Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Abstract Background Vildagliptin and pioglitazone/rosiglitazone are emerging Oral Hypoglycemic Agents (OHAs) which are used to treat patients suffering from Type 2 Diabetes Mellitus (T2DM). In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use...

Descripció completa

Dades bibliogràfiques

Autors principals:	Pravesh Kumar Bundhun, Girish Janoo, Abhishek Rishikesh Teeluck, Feng Huang
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2017-10-01
Col·lecció:	BMC Pharmacology and Toxicology
Matèries:	Vildagliptin Pioglitazone Type 2 diabetes mellitus Adverse drug events Peripheral edema Weight gain
Accés en línia:	http://link.springer.com/article/10.1186/s40360-017-0175-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!